ABL1 and acute lymphoblastic leukemia: NUP214-ABL1 fusion resulting in ABL1 amplification has been described in 5–10% of T-ALL cases [51,52], rendering them sensitive to tyrosine kinase inhibitors Imatinib, Nilotinib, and Dasatinib [53].